Lyell Immunopharma Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Jun 2, 2021
MorphoSys to buy Constellation Pharma for $1.7 billion; Constellation's stock soars 61%
Shares of MorphoSys AG ADR MOR, -12.90% were down 8.9% in premarket trading on Wednesday after the company announced a $1.7 billion...
May 27, 2021
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will...
Apr 13, 2021
Sana Biotechnology Presents Preclinical Data at AACR Meeting 2021
Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen
results in tumor eradication Hypoimmune CAR T cells protected from...
Mar 11, 2021
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for Patients with Malignant Gliomas
NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...
Mar 11, 2021
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treat
Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or...
Feb 17, 2021
GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19
Last year, Big Pharma GlaxoSmithKline and George Scangos’ biotech Vir joined forces against COVID-19. Now, the pair is turning its...
Feb 11, 2021
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol "NUVB" Strong cash position...
Feb 4, 2021
Sana snags $587.5M IPO to catapult cell therapies into the clinic
Massive private raise? Check. Preclinical pipeline? Check. Now, Sana Biotechnology is raising $587.5 million in a mammoth IPO that will...
bottom of page